⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 6,7-Dihydro-5H-Pyrrolo[3,4-B]Pyridine SCHEMBL103669 | 1.00 | — | — | |
| 6,7-Dihydro-5H-Pyrrolo[3,4-B]Pyridine SCHEMBL3809748 | 0.98 | PNMT (0.35) | — | |
| 6,7-Dihydro-5H-Pyrrolo[3,4-B]Pyridine SCHEMBL30582725 | 0.98 | PNMT (0.35) | — | |
| 6,7-Dihydro-5H-Pyrrolo[3,4-B]Pyridine SCHEMBL27709534 | 0.98 | PNMT (0.35) | — | |
| 6,7-Dihydro-5H-Pyrrolo[3,4-B]Pyridine SCHEMBL4573663 | 0.98 | PNMT (0.35) | — | |
| 6,7-Dihydro-5H-Pyrrolo[3,4-B]Pyridine SCHEMBL2704396 | 0.89 | DRD2 (0.37) | — | |
| SCHEMBL588622 | 0.81 | PNMT (0.52) | — | |
| SCHEMBL12822 | 0.81 | PNMT (0.52) | — | |
| SCHEMBL30331914 | 0.81 | PNMT (0.52) | — | |
| Hydrochloric Acid SCHEMBL2378664 | 0.79 | PNMT (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111655695-B | Substituted furopyrimidine compounds as PDE1 inhibitors | 达特神经科学有限公司 | 2025-05-27 | — | — | CN | claimed |
| US-12552758-B2 | Inhibitors of MLH1 and/or PMS2 for cancer treatment | Neophore Limited (GB) | 2026-02-17 | — | — | US | disclosed |
| WO-2025215579-A1 | NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| EP-4584254-A1 | ISOQUINOLONES AS PI3K INHIBITORS | OnKure, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025133961-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS FOR THE TREATMENT OF CHRONIC DISEASES | PFIZER INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-111655695-B | Substituted furopyrimidine compounds as PDE1 inhibitors | 达特神经科学有限公司 | 2025-05-27 | — | — | CN | disclosed |
| WO-2025101942-A1 | KAT6 TARGETING COMPOUNDS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2025-05-15 | — | — | WO | disclosed |
| US-12281122-B1 | PI3K inhibitors | COGENT BIOSCIENCES, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| WO-2025038815-A1 | MUTANT PI3K-ALPHA INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2025-02-20 | — | — | WO | disclosed |
| WO-2025029683-A1 | PI3K INHIBITORS | COGENT BIOSCIENCES, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| WO-2024054469-A1 | ISOQUINOLONES AS PI3K INHIBITORS | ONKURE, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024051717-A1 | COMPOUND AS PLK1 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海深势唯思科技有限责任公司 | 2024-03-14 | — | — | WO | disclosed |
| EP-4267585-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | Actelion Pharmaceuticals Ltd (CH) | 2023-11-01 | — | — | EP | disclosed |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2023-06-22 | — | — | US | disclosed |
| US-20230183197-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | Neophore Limited (GB) | 2023-06-15 | — | — | US | disclosed |
| WO-2023015283-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE DEGRADATION OF ENGINEERED PROTEINS | CELGENE CORPORATION (US) | 2023-02-09 | — | — | WO | disclosed |
| US-11566020-B1 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | disclosed |
| WO-2022136509-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022105857-A1 | KRAS G12D INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-05-27 | — | — | WO | disclosed |